Proportion of patients free of new/newly enlarged T2 lesions, n (%) 

A

Proportion of patients relapse-free, n (%) 

B

Cumulative number of new/newly enlarged T2 lesions, mean (SD) 

C

Annualized relapse rate 

D

Placebo–fingolimod 0.5 mg (N = 23) 
Placebo–fingolimod 1.25 mg (N = 20) 
Continuous fingolimod 0.5 mg (N = 45) 
Continuous fingolimod 1.25 mg (N = 42)